CPC Subgroup Additional Only
C07K 2317/70 characterized by effect upon binding to a cell or to an antigen
Full Title
Immunoglobulins specific features > characterized by effect upon binding to a cell or to an antigen
7 direct subcodes
Child Classifications
Navigate with arrow keys, Enter to open
- C07K 2317/71 Decreased effector function due to an Fc-modification
- C07K 2317/72 Increased effector function due to an Fc-modification
- C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/74 Inducing cell proliferation
- C07K 2317/75 Agonist effect on antigen
- C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77 Internalization into the cell
Top Applicants
Top 10 applicants by patent filingsfor class C07, 2013–2023, worldwide · Source: EPO PATSTAT
- ROCHE CH 12,683
- NOVARTIS CH 10,775
- CHINESE ACADEMY OF SCIENCES 10,619
- BASF (BADISCHE ANILIN & SODA FABRIK) DE 9,511
- REGENERON PHARMACEUTICALS US 8,426
- BRISTOL-MYERS SQUIBB COMPANY US 7,979
- LG CHEM KR 7,978
- HARVARD UNIVERSITY US 7,706
- UNIVERSITY OF CALIFORNIA US 7,455
- SINOPEC (CHINA PETROCHEMICAL CORPORATION) 7,219